My almost 11 year old daughter has had diabetes for the last year and a half. She takes 17 units of Lantus at lunch time, four units of NovoRapid for breakfast, five units of NovoRapid for lunch, and four units of NovoRapid for dinner. Her A1cs have ranged from 6.9 to 7.1. She he 141 cm (4 feet, 6 inches) and she weighs 35 kg (77 pounds). Her doctor says her control is good except for the few highs before lunch when her Lantus is wearing off.
Recently, I started giving her two ounces of pure aloe vera juice in the morning and she has had better pre-lunch readings. Is there any correlation between the insulin and the aloe vera? My pharmacist sells this and also gave me information about other herbal products, some of which make it possible for people to take less insulin. Is this true? I was only giving my daughter the juice as an immune booster.
As far as I know from recent literature, aloe vera, a tropical cactus native to North Africa and also cultivated in Turkey, might be of some help in type 2 diabetes through some hypoglycemic agent not yet identified. This is effective because someone with type 2 usually has a residual insulin secretion while someone with type 1 does not. A positive influence of aloe vera has been described towards the healing of dermal wounds in diabetic patients probably due to its likely anti-inflammatory activity. I'd not recommend aloe vera juice for your daughter.
Original posting 23 Jan 2006
Posted to Other
|Return to the Top of This Page|
Last Updated: (none)
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.